Natco Pharma Expands Oncology Portfolio with New Multiple Myeloma Drug

has announced the launch of its new drug for the treatment of adult patients suffering from multiple myeloma, further strengthening its oncology portfolio and reinforcing its focus on specialty therapies. The company introduced the product in the Indian market following necessary regulatory approvals, targeting improved accessibility and affordability in the blood-cancer treatment segment. The development is strategically important as multiple myeloma remains a high-value oncology category globally, and such launches typically support portfolio depth and long-term growth visibility for the company.